Sichuan Biokin - Public Comps and Valuation Multiples

Sichuan Biokin Overview

About Sichuan Biokin

Sichuan Biokin Pharmaceutical Co Ltd is a chemical drug and biological drug-based company that integrates drug research and development, production and marketing.

Founded

2006

HQ

Employees

n/a

Website

en.baili-pharm.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $355M

LTM EBITDA $535M

EV

$21.2B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Sichuan Biokin Financials

As of November 2025, Sichuan Biokin reported last 12-month revenue of $355M and EBITDA of $535M.

In the same period, Sichuan Biokin generated $323M in LTM gross profit and -$6.1M in net income.

See Sichuan Biokin valuation multiples based on analyst estimates

Sichuan Biokin P&L

In the most recent fiscal year, Sichuan Biokin reported revenue of $823M and EBITDA of $579M.

Sichuan Biokin expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Sichuan Biokin valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$355M	XXX	$823M	XXX	XXX	XXX
Gross Profit	$323M	XXX	$786M	XXX	XXX	XXX
Gross Margin	91%	XXX	95%	XXX	XXX	XXX
EBITDA	$535M	XXX	$579M	XXX	XXX	XXX
EBITDA Margin	151%	XXX	70%	XXX	XXX	XXX
EBIT	-$4.6M	XXX	$529M	XXX	XXX	XXX
EBIT Margin	-1%	XXX	64%	XXX	XXX	XXX
Net Profit	-$6.1M	XXX	$524M	XXX	XXX	XXX
Net Margin	-2%	XXX	64%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Sichuan Biokin including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $355M. EBITDA for the last twelve months was $535M. In the most recent fiscal year, Sichuan Biokin achieved $823M in revenue and $579M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$355M	Analyst estimates available to subscribers	$823M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$323M	Analyst estimates available to subscribers	$786M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	90.8% gross margin	Analyst estimates available to subscribers	95.5% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$535M	Analyst estimates available to subscribers	$579M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	150.6% EBITDA margin	Analyst estimates available to subscribers	70.4% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$4.6M	Analyst estimates available to subscribers	$529M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-1.3% EBIT margin	Analyst estimates available to subscribers	64.3% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$6.1M	Analyst estimates available to subscribers	$524M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-1.7% net profit margin	Analyst estimates available to subscribers	63.7% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Sichuan Biokin

This financial data table provides comprehensive performance metrics for Sichuan Biokin, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Sichuan Biokin generated $355M in revenue over the last twelve months.
The company achieved $535M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $323M.
Net income over the last twelve months reached -$6.1M.

Fiscal Year Performance

In the most recent fiscal year, Sichuan Biokin reported $823M in total revenue.
Fiscal year EBITDA was $579M.
The company maintained a gross profit margin of 95.5% in the most recent fiscal year.
EBITDA margin for the fiscal year was 70.4%.
Net profit margin reached 63.7% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Sichuan Biokin. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Sichuan Biokin Stock Performance

Sichuan Biokin has current market cap of CNY 153B (or $21.6B), and EV of CNY 150B (or $21.2B).

Market Cap Evolution

Sichuan Biokin Stock Data

As of December 3, 2025, Sichuan Biokin's stock price is CNY 369 (or $52).

See Sichuan Biokin trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$21.2B	$21.6B	XXX	XXX	XXX	XXX	$-0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Sichuan Biokin Valuation Multiples

Sichuan Biokin's trades at 25.8x EV/Revenue multiple, and 36.6x EV/EBITDA.

See valuation multiples for Sichuan Biokin and 15K+ public comps

Sichuan Biokin Financial Valuation Multiples

As of December 3, 2025, Sichuan Biokin has market cap of $21.6B and EV of $21.2B.

Equity research analysts estimate Sichuan Biokin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Sichuan Biokin has a P/E ratio of -3521.2x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$21.6B	XXX	$21.6B	XXX	XXX	XXX
EV (current)	$21.2B	XXX	$21.2B	XXX	XXX	XXX
EV/Revenue	59.7x	XXX	25.8x	XXX	XXX	XXX
EV/EBITDA	39.7x	XXX	36.6x	XXX	XXX	XXX
EV/EBIT	-4593.7x	XXX	40.1x	XXX	XXX	XXX
EV/Gross Profit	65.8x	XXX	n/a	XXX	XXX	XXX
P/E	-3521.2x	XXX	41.1x	XXX	XXX	XXX
EV/FCF	n/a	XXX	37.8x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Sichuan Biokin Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Sichuan Biokin Margins & Growth Rates

Sichuan Biokin's last 12 month revenue growth is -4%

Sichuan Biokin's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Sichuan Biokin's rule of 40 is -125% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sichuan Biokin's rule of X is 142% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Sichuan Biokin and other 15K+ public comps

Sichuan Biokin Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	-4%	XXX	-35%	XXX	XXX	XXX
EBITDA Margin	151%	XXX	70%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	-125%	XXX	67%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	142%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	2%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	25%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	31%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial